shutterstock_1465083494_morumotto
Morumotto / Shutterstock.com
15 March 2022GenericsAlex Baldwin

Otsuka says Samsca generic infringes

Otsuka Pharmaceuticals has filed a patent infringement suit against MSN Laboratories targeting the company’s planned generic Samsca (tolvaptan) heart medication.

Already registered?

Login to your account

To request a FREE 2-week trial subscription, please signup.
NOTE - this can take up to 48hrs to be approved.

Two Weeks Free Trial

For multi-user price options, or to check if your company has an existing subscription that we can add you to for FREE, please email Adrian Tapping at atapping@newtonmedia.co.uk


More on this story

Americas
24 February 2022   Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Americas
3 March 2017   Otsuka Pharmaceutical has agreed to acquire Neurovance, a privately held clinical stage pharma company.

More on this story

Americas
24 February 2022   Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Americas
3 March 2017   Otsuka Pharmaceutical has agreed to acquire Neurovance, a privately held clinical stage pharma company.

More on this story

Americas
24 February 2022   Otsuka Pharmaceutical has sued Teva Pharmaceuticals, alleging that the company’s planned generic of Otsuka’s REXULTI antipsychotic (brexpiprazole) tablets infringe five of its patents.
Americas
3 March 2017   Otsuka Pharmaceutical has agreed to acquire Neurovance, a privately held clinical stage pharma company.